Celldex Therapeutics

Celldex Therapeutics is a clinical-stage biotechnology company that develops antibody-based therapeutics for patients with inflammatory, allergic, autoimmune and other difficult-to-treat diseases. Its lead candidate is barzolvolimab, a monoclonal antibody that targets KIT. It is being studied in chronic spontaneous urticaria, chronic inducible urticaria and other indications. The company's pipeline also includes bispecific antibodies and other earlier-stage programs.